Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Science of MDHAQ/RAPID3 Scores

Theodore Pincus, MD  |  Issue: December 2011  |  December 12, 2011

click for large version
Figure 1: MDHAQ/RAPID3 (available online at www.mdhaq.org).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
click for large version
Figure 2: MDHAQ page 2 (available online at www.mdhaq.org).

Unexpected Observations from a Box of Records

My appreciation of the value of the evolving MDHAQ was greatly accelerated in July 1982 by results of a review of long-term outcomes of RA, which began as a summer research project by a Vanderbilt medical student, Lee Payne. William Sale, MD, an orthopedic resident there, had performed an unusually extensive evaluation, including patient questionnaires, on 75 RA patients nine years earlier in 1973, and gave me a box of their records (labeled “Jim Beam”) before he left Vanderbilt. Our investigation of the patients nine years later revealed five unexpected observations, which presented novel implications for care of patients with RA:9

  1. Long-term outcomes of RA were much more unfavorable than was generally recognized at the time, with severe functional declines and premature mortality rates, predicted by severity of clinical status, rather than by adverse effects of therapies.
  2. Treatment at that time, although described as “remission-inducing” in textbooks, was not adequate for favorable long-term results.10
  3. The most significant quantitative clinical predictor of premature mortality was physical function assessed on a patient questionnaire, rather than radiographs or laboratory tests. Poor physical function scores identified a risk of less than 50% five-year survival in RA similar to stage IV Hodgkin disease or three-vessel coronary artery disease (see Figure 3). Therefore, it seemed reasonable that patient self-report questionnaire scores should be available for clinical decisions at all usual care visits.
  4. Formal education level was more significant in predicting premature mortality than laboratory tests or radiographs (see Figure 3), indicating the importance of socioeconomic status, patient actions, and self-management in the outcomes of RA (and all chronic diseases).11
  5. Results of relatively short-term clinical trials with agents such as gold salts and penicillamine did not translate into favorable long-term outcomes, indicating a need for long-term observational studies to analyze results of treatment and outcomes of RA (and all chronic diseases).

The first two observations—that RA was a severe disease with high rates of work disability and increased mortality and that the therapies available at that time were inadequate—were widely accepted by the rheumatology community; similar reports from other sites helped foster new treatment approaches. The other three observations, however, have been accepted much more slowly over the last 25 years. Patient self-report questionnaires—the most significant predictor of work disability and mortality in RA—have been introduced into only about 20% of rheumatology usual care settings, although at an accelerated rate in recent years. The importance of socioeconomic variables in health, though widely recognized far beyond RA, remains omitted from most reports of clinical trials and outcomes.11 Observational databases have been established to monitor long-term outcomes, but generally as research activities, rather than in the infrastructure of usual care. This seems unfortunate, because simple programs for self-report questionnaires allow documentation of the course of every rheumatology patient, without a need for specialized registries, although analyses of data in groups require additional expertise.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:Diagnostic Criteriaevidence-based medicineHealth Assessment Questionnairepatient carerheumatology

Related Articles

    Remote Use of the Multidimensional Health Assessment Questionnaire (MDHAQ)

    December 18, 2019

    The patient medical history is far more prominent in clinical decisions for rheumatology than for many common chronic diseases in which a gold standard biomarker, such as blood pressure or serum glucose, is applicable to diagnosis and management of all individual patients.1 Components of a subjective patient history may be recorded as structured, quantitative, standard,…

    The Peripatetitc Theodore Pincus, MD

    July 1, 2007

    Tireless champion for patient self-report

    Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?

    April 1, 2013

     Long-term, low-dose prednisone at less than 5 mg/day appears tolerable and effective for many patients with rheumatoid arthritis (RA)

    Glucocorticoid Use in Rheumatoid Arthritis Management Focus of Ongoing Debate

    March 1, 2015

    Questions around prescribing steroids as bridge therapy, in long-term low dosages, or low-dose timed-release formulas, or not at all evoke controversy among rheumatologists

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences